April 23 | 2021
The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021
Read more
March 1 | 2021
2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint.
Read more
February 25 | 2021
2cureX publishes year-end report for 2020.
Read more
February 25 | 2021
2cureX offentliggör bokslutskommuniké för räkenskapsåret 2020.
Read more
February 4 | 2021
IndiTreat® selected to prestigious multinational ovarian cancer project.
Read more
January 28 | 2021
2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO.
Read more
January 5 | 2021
2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO
Read more
November 26 | 2020
2cureX offentliggör delårsrapport för det tredje kvartalet 2020.
Read more
November 26 | 2020
2cureX publishes interim report for the third quarter of 2020.
Read more
November 5 | 2020
Announcement from 2cureX extra general meeting
Read more
November 5 | 2020
Kommuniké från extra bolagsstämma i 2cureX
Read more
October 14 | 2020
Kallelse till extra bolagsstämma i 2cureX AB
Read more
October 14 | 2020
Notice of extraordinary general meeting in 2ureX AB
Read more
October 1 | 2020
Den sista patienten är registrerad med framgång i världens första interventionsstudie med 3D-mikrotumörer som vägledning för val av cancerbehandling.
Read more
October 1 | 2020
Last patient successfully enrolled in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
Read more
August 27 | 2020
2cureX AB (”2cureX”) offentliggör härmed halvårsrapport för det första halvåret 2020
Read more
August 27 | 2020
2cureX AB (“2cureX”) hereby publishes the interim report for the first half of 2020.
Read more
August 4 | 2020
Första dag för handel med teckningsoptioner av serie TO1
Read more